Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Champions Oncology, Inc.NASDAQ: CSBR
EBITDA · Q3 FY2026 · quarter ended Jan 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $104K fell 97.9% year over year, ahead of the -111.2% change in trailing-twelve-month EBITDA. Sequentially, it fell 83.0% from the prior quarter. Over 3 fiscal years it compounded at +41.5% a year.
Context
- EBITDA amounted to 11.0% of revenue in FY2025, up 0.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $3.48M (-44.5%) for the fiscal year ending Apr 2026, a slowdown from the +215.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJan 2026
- $104K-83.0% QoQ
- Last fiscal yearApr 2025
- $6.27M+215.2% YoY
- LTMJan 2026
- -$948K-111.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -97.9% | +76.2% | +174.1 pp |
| 1 year | +215.2% | -44.5% | -259.7 pp |
| 3-year CAGR | +41.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 6.27M USD
- Year-over-year change
- +215.2%
- 4-year CAGR
- +41.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 6.27M | +215.2% |
| FY2024 | 2024-04-30 | (5.44M) | -80.1% |
| FY2023 | 2023-04-30 | (3.02M) | -236.7% |
| FY2022 | 2022-04-30 | 2.21M | +42.6% |
| FY2021 | 2021-04-30 | 1.55M | — |
EBITDA vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -111.2% is the 9th highest of 10, against a peer median of +4.6%.
- EBITDA amounts to 1.6% of revenue for CSBR, versus a peer median of 4623.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M USD | +1391.3% | — | — | |
| LTM Jan 2026 | -$948K USD | -111.2% | +41.5% | 1.6% | |
| LTM Mar 2026 | -$5.48M USD | +4.6% | — | 23.7% | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.08M USD | +36.5% | — | — |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
IMAImageneBio Inc | LTM Mar 2026 | -$51.64M USD | -7.8% | — | — |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M USD | -35.4% | — | — |
| LTM Mar 2026 | -$106.12M USD | +42.0% | — | 106.5% | |
| Peer median (excluding CSBR) | — | +4.6% | — | 4623.1% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Revenue | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M |
| Cost of Revenue | 21.45M | 23.63M | 29.53M | 29.4M | 28.39M |
| Gross Profit | 19.59M | 25.48M | 24.34M | 20.75M | 28.56M |
| Gross Margin | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% |
| Research & Development | 7.2M | 9.37M | 11.55M | 9.54M | 6.83M |
| Selling, General & Admin | 12.03M | 15.5M | 17.24M | 18.13M | 16.88M |
| Operating Expenses | 19.23M | 24.87M | 28.79M | 27.68M | 23.71M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| EBITDA | 1.55M | 2.21M | (3.02M) | (5.44M) | 6.27M |
| EBITDA Margin | 3.8% | 4.5% | -5.6% | -10.8% | 11.0% |
| Operating Income | 366K | 607K | (4.45M) | (6.92M) | 4.85M |
| Operating Margin | 0.9% | 1.2% | -8.3% | -13.8% | 8.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 71K | (24K) | (818K) | (387K) | (220K) |
| Income Before Tax | 437K | 583K | (5.27M) | (7.31M) | 4.63M |
| Pre-Tax Margin | 1.1% | 1.2% | -9.8% | -14.6% | 8.1% |
| Income Tax Expense | 75K | 35K | 68K | (32K) | (75K) |
| Net Income | 362K | 548K | (5.34M) | (7.28M) | 4.7M |
| Net Margin | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% |
| EPS (Basic) | 0.03 | 0.04 | (0.39) | (0.54) | 0.34 |
| EPS (Diluted) | 0.02 | 0.04 | (0.39) | (0.54) | 0.33 |
| Weighted Avg Shares | 13.14M | 13.2M | 13.54M | 13.55M | 13.66M |
| Weighted Avg Shares (Diluted) | 14.57M | 14.16M | 13.54M | 13.55M | 14.27M |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.